Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplerenone for Proteinuria in Progressive Renal Disease
NCT00430924Phase 4
Key facts
- Status
- Completed
- Start
- Mar 2007
- Primary completion
- Aug 2009
- Countries
- 1
- Modality
- Orthosteric Ligands
- Drugs
- eplerenone
- Conditions
- chronic kidney disease (CKD)
01
Overview
Phase 4, randomised, double-blind trial of eplerenone in chronic kidney disease (CKD). Primary endpoint: Proteinuria reduction at 8 weeks. Started Mar 2007; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Patients with non-diabetic chronic kidney disease, proteinuria > 500 mg/24h, and hypertension on stable ACE inhibitor or ARB therapy.
04
Endpoints
Primary
Proteinuria reduction
Beyond the preview
Go deeper on NCT00430924.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00430924.